Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.

Journal article

PURPOSE: To evaluate the prognostic value of cell of origin immunohistochemical markers and BCL2, BCL6, and c-MYC translocations in a homogeneous cohort of patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). PATIENTS AND METHODS: Patients with CD20+ DLBCL were enrolled in the randomized LNH98-5 and 01-5B Groupe d'Etude des Lymphomes de l'Adulte trials. Paraffin-embedded tumor samples of 119 patie...

Expand abstract

Authors: Copie-Bergman, C; Gaulard, P; Leroy, K; Briere, J; Baia, M

• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
• Volume: 27
• Issue: 33
• Pages: 5573-5579
• Publication date: 2009-11-01
• DOI: 10.1200/jco.2009.22.7058
• EISSN: 1527-7755
• ISSN: 0732-183X
• Language: English
• Keywords: Lymphoma, Large B-Cell, Diffuse; Doxorubicin; Proportional Hazards Models; Antineoplastic Combined Chemotherapy Protocols; Severity of Illness Index; Genes, myc; Multivariate Analysis; Biological Markers; Proto-Oncogene Proteins c-bcl-2; In Situ Hybridization, Fluorescence; Survival Analysis; Predictive Value of Tests; Prognosis; Aged; Drug Administration Schedule; Aged, 80 and over; Enzyme-Linked Immunosorbent Assay; Female; Prednisone; Middle Aged; Dose-Response Relationship, Drug; Treatment Outcome; Risk Assessment; Vincristine; Probability; Cyclophosphamide; Antibodies, Monoclonal; Humans; Antibodies, Monoclonal, Murine-Derived; Male